Plain-English translation of NCT07796061 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new approach called LIFT therapy to treat diffuse midline gliomas, aggressive brain tumors that occur in children and young adults. The treatment combines two parts: first, doctors use a specialized ultrasound system (called Exablate) paired with tiny bubbles to carefully open the blood-brain barrier—a protective barrier around the brain—to allow medicine to reach the tumor more effectively. Then, specially trained immune cells called TAA-T cells are infused into the bloodstream to attack the cancer.
Diffuse midline gliomas are very difficult to treat because the blood-brain barrier normally blocks most medicines from reaching tumors in this part of the brain. This trial exists to test whether opening this barrier temporarily with ultrasound, combined with immune cell therapy, can help more of the body's cancer-fighting cells reach and destroy the tumor.
You likely qualify if…
You likely don't qualify if…
You would start by having blood drawn to create your personalized immune cells in the laboratory—this takes several weeks. Then you would receive up to three cycles of LIFT therapy, where each cycle involves coming to the hospital for the ultrasound procedure followed by an IV infusion of your immune cells about 30 minutes to 4 hours later. After each treatment, you would stay in the hospital or be closely monitored for at least 28 days to check for any side effects. The total treatment can take several months depending on how well the cells are made and how you respond.
AI-generated summary from trial data · Nov 3, 2026 · Not medical advice
United States